Shire Solid But Hemophilia Challenges Looming?

Shire puts in solid results in last full year before Takeda acquisition, with 4% sales growth and strong cash flow, but there was some weakness in hematology stemming from lower ex-US prices and rising competition.

Takeda HQ
Shire Grows In Last Pre-Takeda Period • Source: Scrip

In the last set of stand-alone annual figures ahead of the completion of its acquisition by Takeda Pharmaceutical Co. Ltd. in early January, Shire PLC logged 4% growth in global product sales to $4.6bn, driven mainly by new products and neuroscience, although there were some wobbles in the hemophilia franchise, which was affected by prices and competition.

On the plus side, major approvals during the year included Takhzyro (lanadelumab-flyo), a first-in-class antibody to prevent hereditary angioedema (HAE),...

More from Strategy

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By 

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Madrigal Regains Lead With Rezdiffra MASH Approval In EU

 
• By 

Four days after Wegovy became the second approved MASH therapy in the US, Rezdiffra gets the first European approval. Plans are for an initial launch in Germany.

Celldex Bullish On Barzolvolimab Despite Study Miss

 
• By 

All eyes on chronic urticaria after eosinophilic esophagitis disappointment.

Glenmark Fortifying Branded Play, Shifts Focus To High Margin Products

 

Glenmark signals thrust on high margin products, while exiting tail end brands as part of efforts to emerge as a branded company. In-licensed assets like Brukinsa and Tevimbra are seen as pivotal to driving growth alongside.

More from Business